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presence of an arteriovenous graft were significant predictorsThe acute-phase response varies with time and predicts serum
that were associated with reduced albumin.albumin levels in hemodialysis patients.
Conclusions. The acute-phase response is intermittent andBackground. Cross sectional studies have established that
is not a continuous feature in individual dialysis patients. Levelsthe serum albumin level is dependent on serum levels of acute-
of APPs are the most powerful predictors for the levels ofphase proteins (APPs) or cytokine levels in hemodialysis pa-
albumin concentration in hemodialysis in a longitudinal setting.tients. While the acute-phase response is generally associated
Since variations in albumin are small, measurement of varia-with acute inflammatory events, a cross sectional analysis relat-
tions in APPs may provide greater insight into the dynamicsing laboratory values to outcomes assumes these values to be
of clinically relevant processes.unchanging. The longitudinal relationship among laboratory
measurements and how they vary over time in a population
of patients are unknown.
Methods. Patients who were enrolled in the HEMO Study Hypoalbuminemia is a powerful predictor of death [1]
were recruited into an ancillary longitudinal study to establish and has been associated with as much as a 20-fold in-
the predictive effect of temporal variation in the levels of APPs crease in the relative risk of death [2]. It has been sug-and of temporal variation in normalized protein catabolic rate
gested that malnutrition, evidenced by hypoalbumi-(nPCR) on the serum albumin concentration. nPCR was mea-
nemia, plays a role in mortality. While hypoalbuminemiasured monthly using a double-pool method. The positive
APPs—C-reactive protein (CRP), a1 acid glycoprotein (a1- and malnutrition have been used nearly synonymously
AG), and ceruloplasmin—and the negative APP—transferrin [3], there is strong evidence that inflammation also plays
(Trf)—were measured in serum obtained before each dialysis a role in determining the level of serum albumin in hemo-
session for six weeks and then monthly in 37 hemodialysis dialysis patients [4–6]. Both C-reactive protein (CRP)patients. A random coefficient regression analysis was used to
levels [4, 5] and cytokine levels [6] are predictive ofassess the association of serum albumin with other measured
temporal variation in albumin concentration in cross sec-parameters at each time point, as well as fixed patient character-
istics. tional studies, and they also predict survival [6, 7]. We
Results. The within-subject coefficients of variation of albu- previously reported that the levels of acute-phase pro-
min (median, range of 25th to 75th percentiles; median, 0.0614; teins were increased in only about 30% of hemodialysis
range, 0.0485 to 0.0690) were significantly less than that of patients [4]. Others have found a similar proportion ofAPPs (CRP, median, 0.878; range, 0.595 to 1.314, P , 0.05;
dialysis patients exhibiting evidence of inflammationand a1 AG, median, 0.173; range, 0.116 to 0.247, P , 0.05).
[7, 8].The levels of APPs and albumin varied considerably over time.
The primary predictor of current albumin was the current CRP Both CRP and cytokine levels also predict cardiovas-
level (P 5 0.0014). nPCR also was a significant predictor for cular disease in patients without renal failure [9–12], as
albumin levels (P 5 0.0440) after controlling for the effect of well as mortality from vascular disease [9–13]. Among
APPs, suggesting an effect of nPCR on serum albumin concen- patients with renal failure, those with elevations in CRPtration irrespective of the acute-phase response. Age and the
or those with hypoalbuminemia also have a significant
increase in vascular disease [8], as well as an increase
in cardiovascular death [7]. It has been postulated thatKey words: C-reactive protein, inflammation, transferrin, a1 acid glyco-
protein, vascular access, nPCR albumin. inflammation is either a cause or a consequence of endo-
thelial dysfunction and/or vascular disease [14]. Approxi-Received for publication October 20, 1999
mately 30% of hemodialysis patients have increased lev-and in revised form January 18, 2000
Accepted for publication January 25, 2000 els of CRP [4, 7, 8], consistent with the increased
prevalence of vascular disease in this population [15].Ó 2000 by the International Society of Nephrology
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Furthermore, the serum albumin concentration also cor- tic kidney disease, and one had analgesic nephropathy.
One patient had end-stage renal disease (ESRD) of un-related with normalized protein catabolic rate (nPCR),
independently of CRP, in our cross sectional analysis known (unassigned) etiology, and the remainder (10)
were diabetic and were presumed to have diabetic renal[4]. Clearly, inflammation may affect appetite and thus
cause both a direct suppression of albumin synthesis and disease.
Kt/V was measured monthly, but we were not permit-a decrease in nPCR, presuming that the latter reflects
protein ingestion. ted to analyze any outcome using that variable, since it
was part of the randomization scheme of the HEMOAll of the published studies have been based on cross
sectional analysis following a single measurement. It is study and the investigators were blinded to that pa-
rameter.unknown whether this evidence of inflammation repre-
sents a chronic condition or instead an indicator for sin- All of the patients were anuric, so urinary protein
losses did not perturb serum protein concentrations.gle or multiple acute processes. Indeed, it is unknown
whether activation of the acute-phase response, as mea-
Laboratory methodssured by increased CRP levels, is a consequence of
chronic infection or of chronic inflammation as might Albumin was measured in duplicate using bromcresol
green. All other proteins were measured with rate nephe-result from underlying endothelial dysfunction, or in-
stead represent an acute time-limited process. We ad- lometry using a Beckman Array automated nephelome-
ter [17]. All nephelometric measurements were made indress the temporal variability of the acute-phase re-
sponse and the nPCR, as well as its relationship to duplicate in each of two optical systems. The average of
these values was used for calculations.albumin concentration at each point in time in a group
of dialysis patients.
Plasma volume measurements
Plasma volume was determined at the time of the
METHODS
first measurement of acute-phase proteins (APPs) by an
Patient selection intravenous injection of [125I] human serum albumin as
described previously [18]. A 10 mCi bolus of [125I] humanPatients enrolled in the HEMO study sponsored by the
National Institutes of Health in two of the participating albumin was injected, and blood samples were drawn at
5, 15, 30, and 60 minutes. The serum was separated andcenters, one at the University of California Davis (Sacra-
mento, CA, USA), and the other at Beth Israel Medical counted in a g counter. The plasma was counted in tripli-
cate. Plasma volume was calculated by regression to zeroCenter (New York, NY, USA), were recruited to partici-
pate in this ancillary longitudinal study. During the first time. Weight at the time of measurement in kilograms
was used to calculate plasma volume in percent.six weeks of observations, albumin, transferrin (Trf),
CRP, a1-acid glycoprotein (a1-AG), and ceruloplasmin The mean value for each protein and for nPCR was
calculated for each patient. The median and range of(Cer) were each measured weekly. Following that pe-
riod, each protein was measured monthly on serum ob- each parameter were calculated from the mean for each
parameter for each patient.tained from predialysis samples. nPCR was measured
monthly using a double-pool method [16].
Statistical methodsTwo patients were dialyzed using a CA210 dialyzer,
and four were dialyzed using a CT190G dialyzer (Baxter From longitudinal measurements of albumin, CRP,
a1-AG, Cer, Trf, and nPCR on 37 dialysis patients, weHealthcare Corporation, Deerfield, IL, USA). All of
these were subjected to reuse with bleach/formaldehyde. conducted a random coefficient regression analysis [19]
in an attempt to determine how well the albumin concen-Ten patients were dialyzed with F8 dialyzers (Fresenius
Medical Care AG, Bad Homburg, Germany) reused with tration at each point in time could be established by the
other measures. This method assumed that each subjectbleach/formaldehyde, four with F8 dialyzers reused with
citric acid, and one with an F6 dialyzer without reuse. had his/her own set of regression coefficients that were
random variables all following the same joint populationSeven patients were dialyzed with a F80B dialyzer reused
with bleach/formaldehyde and nine with an F80A dia- distribution. Considering the random coefficients to be
nuisance parameters, our interest was in generating thelyzer reused with citric acid.
All dialysis was performed using a bicarbonate-based fixed effects coefficients and determining the contribu-
tion of the fixed effects in describing the association ofdialysate at a delivered bicarbonate concentration of
39 mEq/L. serum albumin with concurrently measured predictor
variables. We also wanted to determine whether any ofNine patients had glomerulonephritis as the cause for
renal failure. Of these, one had heroin nephropathy. a set of fixed demographic and medical variables in-
cluded at the start of the study played a role in describingFour patients had renal failure caused by hypertension.
Two patients had hereditary nephritis. Two had polycys- albumin concentration. These variables included patient
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gender, ethnicity, age, and vascular access at the time of
entry, presence or absence of diabetes, and body mass
index (BMI). Additional details are given in the Ap-
pendix.
The modeling was performed in two stages. First, we
tried to find the best model for predicting the measured
albumin concentration at each time point using only the
longitudinally measured physiological variables (that is,
CRP, a1-AG, Cer, Trf, and nPCR) as predictors. Here,
we used stepwise forward variable selection using the
Akaike Information Criterion (AIC Criterion), which is
a commonly used model selection criterion that penalizes
models for containing too many predictors. In a second
step, after obtaining the best model based on the physio-
logical variables, the demographic variables and other
patient characteristics were considered as additional pre-
dictors. These variables were considered for inclusion in
Fig. 1. Relationship between initial plasma volume measured by iso-the model as fixed effects. Ethnicity was divided into tope dilution ([125I] human serum albumin) and initial serum albumin
white, black, and Hispanic. Asian patients formed the concentration (R2 5 0.00355; P 5 NS).
baseline group for ethnicity against which the other eth-
nicities were compared.
Finally, coefficient of variations (CVs) for each protein
the concentration of each protein and for nPCR areand nPCR were measured. Differences between CVs
presented in Table 2.were assessed by pair-wise t-tests for dependent data.
Neither the serum albumin concentration nor that of
APPs was constant. The levels of APPs varied consider-
ably over time (Fig. 2). Variances in CRP were twoRESULTS
orders greater than that of albumin or Trf, and variancesThe patients ranged in age from 19 to 81 years, with
in a1-AG were one order of magnitude greater thana median of 59 years. The 25th and 75th percentiles were
that of albumin (Fig. 2). The acute-phase response was49.5 and 69 years, respectively. The BMIs of the patients
usually of limited duration (Fig. 3). Figure 3 shows theranged from 16.6 to 33.3 kg/m2, with a median value of
temporal relationships between albumin and CRP levels24.5 kg/m2. The 25th and 75th percentiles were 21.1 and
in 12 consecutive patients in whom CRP values varied27.2 kg/m2, respectively. There were no significant differ-
by a minimum of one order of magnitude. At each point
ences in these values in the patients enrolled in the two
in time, the concentration of serum albumin was associ-
study centers. ate with the current levels of the APPs and nPCR. Of
Plasma volume was 4.95 6 1.16%, with a range of 2.93 these, CRP was the strongest predictor of serum al-
to 8.05% body weight. There was no correlation between bumin.
plasma volume and plasma albumin concentration (r 2 5 The between-assay CV for the CRP assay was less than
0.00355, P 5 0.726; Fig. 1). 2% and for that of the albumin assay was less than 3%.
There was a total of 20 patients who had arteriovenous The fixed effects parameter estimates and P values
(AV) grafts, 12 with AV fistulas and 5 with transcutane- for tests of significance are reported in Table 3. Note
ous access (catheters). Fifteen patients had diabetes mel- that the model fitting included both fixed and random
litus, and 22 did not. The mean time that patients had effects. The predictors listed in Table 2 resulted in the
been on hemodialysis at the initiation of this study (mea- best overall model fit only from the longitudinal pre-
surement of plasma volume followed by subsequent de- dictors (after incorporating a penalty for including too
termination of serum proteins) was 57.8 months, with a many variables in the model via AIC). The CRP coeffi-
range of 117.3 months (minimum 10.3 months, maximum cient estimate was negative and highly significant, indi-
127.6 months, 75th percentile 76.2 months, 25th percen- cating a strong inverse relationship between albumin and
tile 41.3 months). There was no difference in the time CRP. Additionally, the nPCR coefficient estimate was
of initial of dialysis and the start of this study between significantly positive. The Cer and a1-AG coefficient
the patient population at Beth Israel Medical Center estimates were small and insignificant.
and the population at UC Davis Medical Center. Ethnic Concerning fixed parameters, ethnicity, gender, the
and gender demographic data are presented in Table 1. presence of diabetes, and BMI failed to achieve signifi-
cance. Both age and the presence of an AV graft wereThe median and range (25th and 75th percentile) for
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Table 1. Demographic characteristics of patients by ethnicity, gender and hemodialysis center
Location Ethnicity Female Male Subtotal Total
University of California Davis African American 5 6 11
Asian 1 2 3
Hispanic 3 3
White 2 5 7 24
Beth Israel African American 5 3 8
Hispanic 3 3
White 1 1 2 13
A total of 37 hemodialysis patients who had been entered into the HEMO study were entered into an ancillary study in which the concentration of a group of
acute phase proteins were measured longitudinally over time.
Table 2. Median values and range for each parameter
Range of means of the Means of the
parameters parameters
Median of the
Parameter 25th 75th means
Albumin 3.91 g/dL 4.29 g/dL 4.08 g/dL
CRP 0.364 mg/dL 2.05 mg/dL 0.991 mg/dL
a1-AG 93 mg/dL 149 mg/dL 117 mg/dL
Ceruloplasmin 33.9 mg/dL 48.6 mg/dL 37.7 mg/dL
Transferrin 169 mg/dL 207 mg/dL 186 mg/dL
nPCR 0.801 1.04 0.897
The mean value for each protein and for nPCR was calculated for each patient.
The median and range of each parameter was calculated from the mean for each
parameter for each patient. The 25th and 75th percentile and median for the
concentrations of the proteins and for nPCR (parameters) are presented.
significant in predicting albumin concentration and were
included in the final model (Table 4). Specifically, the
included nonlongitudinal predictors, age and vascular
Fig. 2. Coefficients of variation of albumin (Alb), transferrin (Trf), C-access, were instrumental in predicting the base level of
reactive protein (CRP), a1-acid glycoprotein (a1-AG), ceruloplasmin
albumin. In the fitted model, this predicted baseline was (Cer), and normalized protein catabolic rate (nPCR) during sequential
measurements in 37 patient on hemodialysis. Results are presented asthen added to the time-varying effects on albumin by
means and standard deviations; *P , 0.05 vs. albumin.the longitudinal predictors. With age and access added
as predictors, the model fit improved on the model that
contained only the longitudinal predictors, CRP, nPCR,
Cer, and a1-AG, according to the AIC criterion. Other DISCUSSION
variables considered did not improve on this new model. Several groups have reported evidence that inflamma-
It should be noted that at this point, it cannot be excluded tion is responsible for establishing serum albumin con-
that once the sample size grew, some of the variables centration in patients on hemodialysis in cross sectional
that were omitted in the current model, such as ethnicity studies [4–6, 8]. To our knowledge this is the first longitu-
or BMI, and especially the presence of a transcutaneous dinal observation of the acute-phase response, as mea-
access (catheter), could eventually reach statistical sig- sured by APPs, in this patient population in which the
nificance. of the relationship between albumin concentration and
As a final note, we looked at the possibility of lagged that of APPs and of nPCR at each time point has been
predictors in the random coefficient regression model. made. It has been proposed that the dialysis process
For example, do changes in CRP temporally precede is directly responsible for inflammation in hemodialysis
changes in albumin? We found that none of the lagged patients [20–22]. Our data would instead suggest that
predictors were of additional predictive value for albu- transient processes are responsible for activation of the
min change. The absence of an influence of previous acute-phase response in the cohort of patients examined
levels of CRP on current albumin levels may have been a here. The acute-phase response generally spanned a pe-
consequence of the time interval between measurements riod of several dialysis treatments, a finding that is incon-
(up to 1 month) in the study and also reflected the posi- sistent with an intradialytic cause of inflammation. CRP
has recently been associated with vascular disease intive correlation of adjacent measurements.
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Table 3. Fixed effect parameter estimates
Approximate
Value standard error Z ratio P value
Intercept 3.964 0.2003 19.796
CRP 20.036 0.0122 22.956 0.0031
nPCR 0.230 0.1031 2.227 0.0259
Ceruloplasmin 0.00203 0.0042 0.477 0.6334
a1-AG 20.00056 0.0011 20.487 0.6263
The results of a random coefficient regression analysis based solely on the
longitudinal measurements to determine how well albumin levels over time were
determined by changes in the other measures. This method assumed that each
subject had his/her own set of regression coefficients that were random variables
all following the same joint population distribution. We utilized a stepwise for-
ward variable selection, resulting in a model that contained CRP, nPCR, cerulo-
plasmin, and a1-AG as predictors. The model fitting techniques factor in both
the fitting of the fixed and random effects. So, even though two of the above
four fixed effect estimates are not considered statistically significant, this particu-
lar group of variables resulted in the best overall model fit.
Table 4. The final model for explaining the variation in albumin
concentration over time
Estimates
Fixed effects Value Standard error Z ratio P value
(Intercept) 4.4053 0.2418 18.222
CRP 20.0390 0.0122 23.196 0.0014
nPCR 0.2115 0.1050 2.014 0.0440
Cer 0.0041 0.0039 1.066 0.2866
a1-AG 20.0007 0.0011 20.621 0.5347
Age per year 20.0057 0.0026 22.224 0.0261
Graft N 5 20 20.2388 0.0833 22.869 0.0041
Catheter N 5 5 20.1994 0.1234 21.616 0.1060
After obtaining the best model based on the longitudinal physiological vari-
ables, a variety of demographic variables and other patient characteristics were
considered as additional fixed effects predictors. The only variables that remained
in the final model were age and type of vascular access.
patients without renal failure [9–11]. Cardiovascular
mortality predictions have been based on a single mea-
surement, suggesting that a single episode of inflamma-
tion either is reflective of underlying vascular disease that
only intermittently expresses itself by overt activation of
the acute phase response or that intermittent inflamma-
tion leads to pathologic vascular change that subse-
quently leads to mortality. Stenvinkel et al established
that CRP levels correlated with carotid artery structure,
as assessed by ultrasonography in dialysis patients [8].
This finding would suggest either that vascular disease
predisposes patients to both episodic increases in CRP
levels and also separately to subsequent morbidity from
that vascular disease or, if inflammation in their popula-
tion occurs in a pattern that is similar to what we report
Fig. 3. Temporal variation in serum albumin concentration (d, g/dL)
and CRP concentration (s, mg/dL) in 12 consecutive hemodialysis
patients in whom CRP changed by at least one order of magnitude
during the period of observation.
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here, that transient inflammatory processes lead to de- concentration and of mortality [9, 10]. All of these obser-
monstrable vascular disease quite quickly. vations have been based on cross-sectional analysis of
The half-lives of cytokines and of the APPs are quite data. These previous observations suggest that even a
short, and their total body masses are quite small in single episode of activation of the acute-phase response
comparison to that of albumin [23–26], and in the cases has lethal potential that is easily identifiable in relatively
of CRP and serum amyloid A (SAA), the biological small populations [9, 10] and that may occur even follow-
range in values varies by up to 1000-fold [27]. For that ing the resolution of that acute episode. This is surprising
reason, changes in the albumin fractional catabolic rate considering the fact that CRP levels vary and are in-
or in the rate of albumin synthesis require considerable creased for only a fraction of time in any given dialysis
time to be seen. Furthermore, the biological range of patient.
albumin synthetic rates, fractional catabolic rates, and
Reprint requests to George A. Kaysen, M.D., Ph.D., Division ofserum values are much smaller than those of either CRP Nephrology, TB 136 Davis, CA USA, University of California Davis,
or cytokines. This we believe is the reason for the con- Davis, California 95616, USA.
E-mail: gakaysen@ucdavis.edutrast in variances between albumin and Trf on one hand
and the positive APPs we measured on the other.
Clearly, a measurement of CRP not only correlates with APPENDIX
low albumin levels [4, 5, 7, 8], but because the variability
The form of the random coefficients regression model is as follows:in CRP is far greater than that in albumin, it is easier
yij 5 (b0 1 bi0) 1 (b1 1 bi1) xij1 1 (b2 1 bi2)xij2 1 . . .to detect events that may lead to morbidity by measuring
this parameter. The greater range of CRP values with 1 (bq 2 1 1 bi,q 2 1)xij,q 2 1 1 bqxijq 1 . . . 1 br21xijr21 1 e ij (1)
similar precision in the two assays may make it a more
where yij represents the albumin concentration for patient i at time j;
sensitive clinical indicator of morbidity than is albumin. xijk represents the kth predictor (for example, CRP) for patient i at time
j; b0 is the population average intercept. b1, b2, . . . , bq21 are theIt should be noted that measurement of limitations of
population average slopes corresponding to longitudinal physiologicalour study design could not enable us to use CRP levels
measurements. bq, bq11, . . . , br21 are the population average slopesto predict future albumin concentrations, since measure- for the fixed predictors (that is, demographic and other prestudy mea-
surements). bi0 is the random effects intercept term for patient i, andments of both proteins were made at one month intervals.
bi1, bi2, . . ., bi,q21 are the random effects slope terms for patient i. ThereNormalized protein catabolic rate, a marker of nitro-
are a total of q random effects and r fixed effects. Finally, e ij is thegen intake at steady state, also has described albumin within-subject error term for patient i at time j. Assuming the e ij are
independent of the bi 5 (bi0, bi1, . . . , bi,q21)t , N(0, D), where D isconcentration at each time point, consistent with our
the covariance matrix of the random effects. We assume e i 5 (e i1, e i2,previous single cross sectional study [4]. However, we
. . ., e ini)t , N(0, s2Li), where ni 5 number of observed times for patientfound no evidence for an interaction of the effects of i. Since it is likely that a positive within-subject correlation exists and
nPCR and CRP. Thus, two separate processes, inflam- owing to the fact the designs varied from patient to patient, we found
it appropriate to model the within-subject correlation, represented bymation and reduced protein catabolism, most likely
Li, with an AR1-continuous process.reflect the reduced protein intake, each separately con- Note that all analyses were performed using the linear mixed effects
tributing to cause a decrease in serum albumin concen- model function, lme(), in S-Plus, version 4.5 [31, 32].
tration.
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